https://www.selleckchem.com/products/KU-60019.html
Adjuvant sorafenib may further enhance the efficacy of transarterial radioembolization for the treatment of hepatocellular carcinoma. To evaluate the efficacy and safety of radioembolization plus sorafenib in hepatocellular carcinoma patients. With a literature search through October 2020, we identified 9 studies (632 patients). Primary outcome was overall survival. Results were expressed as pooled median, odds ratio, or hazard ratio and 95% confidence intervals. Pooled overall survival after radioembolization plus sorafenib was 10.79
Like
Comment
Share
